EcoR1 Capital LLC acquired a new stake in Viveve Medical, Inc. (NASDAQ:VIVE) during the first quarter, according to its most recent 13F filing with the SEC. The firm acquired 250,000 shares of the company’s stock, valued at approximately $1,583,000. Viveve Medical comprises approximately 0.4% of EcoR1 Capital LLC’s investment portfolio, making the stock its 22nd largest position.
A number of other large investors also recently modified their holdings of VIVE. Granahan Investment Management Inc. MA increased its stake in shares of Viveve Medical by 8.0% in the first quarter. Granahan Investment Management Inc. MA now owns 396,494 shares of the company’s stock valued at $2,510,000 after buying an additional 29,364 shares during the period. Perceptive Advisors LLC bought a new stake in shares of Viveve Medical during the first quarter valued at about $5,942,000. Stonepine Capital Management LLC increased its stake in shares of Viveve Medical by 48.1% in the first quarter. Stonepine Capital Management LLC now owns 3,849,711 shares of the company’s stock valued at $24,256,000 after buying an additional 1,250,000 shares during the period. Vanguard Group Inc. increased its stake in shares of Viveve Medical by 924.4% in the first quarter. Vanguard Group Inc. now owns 191,230 shares of the company’s stock valued at $1,210,000 after buying an additional 172,562 shares during the period. Finally, Wexford Capital LP increased its stake in shares of Viveve Medical by 23.9% in the first quarter. Wexford Capital LP now owns 777,124 shares of the company’s stock valued at $4,919,000 after buying an additional 150,000 shares during the period. Hedge funds and other institutional investors own 61.19% of the company’s stock.
Shares of Viveve Medical, Inc. (NASDAQ:VIVE) traded up 3.95% during midday trading on Friday, reaching $7.90. 192,523 shares of the company’s stock traded hands. Viveve Medical, Inc. has a 12 month low of $3.75 and a 12 month high of $11.16. The stock has a 50-day moving average price of $7.66 and a 200 day moving average price of $5.96. The firm’s market cap is $152.90 million.
Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings data on Thursday, May 11th. The company reported ($0.57) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by $0.06. The business had revenue of $3.04 million during the quarter, compared to the consensus estimate of $2.70 million. Viveve Medical had a negative return on equity of 232.94% and a negative net margin of 255.11%. Equities research analysts predict that Viveve Medical, Inc. will post ($1.81) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “EcoR1 Capital LLC Invests $1.58 Million in Viveve Medical, Inc. (VIVE)” was first reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://sleekmoney.com/ecor1-capital-llc-invests-1-58-million-in-viveve-medical-inc-vive/1916395.html.
Several brokerages have issued reports on VIVE. B. Riley restated a “buy” rating and set a $10.00 price objective on shares of Viveve Medical in a research report on Friday, May 12th. Cowen and Company began coverage on shares of Viveve Medical in a research report on Wednesday, May 3rd. They set an “outperform” rating and a $11.00 price objective for the company. ValuEngine upgraded shares of Viveve Medical from a “sell” rating to a “hold” rating in a research report on Friday, June 9th. Finally, Raymond James Financial, Inc. began coverage on shares of Viveve Medical in a research report on Thursday, May 25th. They set an “outperform” rating and a $10.00 price objective for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Viveve Medical presently has an average rating of “Buy” and a consensus price target of $12.80.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Want to see what other hedge funds are holding VIVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viveve Medical, Inc. (NASDAQ:VIVE).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/ecor1-capital-llc-invests-1-58-million-in-viveve-medical-inc-vive/1916395.html
Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.